Sulzer and Emirates Biotech advance strategic partnership with equipment supply contract for world’s largest bioplastics facility

Sulzer will manufacture and supply the essential proprietary equipment for the integrated PLA production process from lactic acid

Sulzer has recently signed a supply contract with Emirates Biotech to provide the proprietary equipment that will serve as the technological core of the world-scale Polylactic Acid (PLA) production facility being built by Emirates Biotech in the United Arab Emirates. This follows a licensing agreement signed in December 2024, reinforcing the strategic partnership between the two companies.

This strategic milestone confirms Emirates Biotech’s transition from early planning to active project execution. Sulzer will manufacture and supply the essential proprietary equipment for the integrated PLA production process from lactic acid, which includes lactide formation, purification and polymerization technology.

As a global leader in separation and polymerization technologies, Sulzer will deliver a full suite of proprietary equipment designed to maximize output, minimize energy use and support Emirates Biotech’s goal of providing renewable, recyclable and biodegradable plastics at industrial scale.

Tim Schulten, Division President Sulzer Chemtech, added: “We are proud to further advance our ongoing collaboration with Emirates Biotech on this pioneering project. Sulzer’s proven PLA technology was selected to enable reliable, efficient production while contributing to global efforts to decarbonize material supply chains. This project represents the kind of bold, solutions-driven investment that can make a real difference.”

From left to right, François de Bie, CCO Emirates Biotech; Dorus Everwijn, President GBI; Marc Verbruggen, CEO Emirates Biotech; Tim Schulten, Division President Sulzer Chemtech; Emmanuel Rapendy, Head Polymer and Crystallization, Sulzer Chemtech and Christophe Miegeville, EPC Project Officer Emirates Biotech
From left to right, François de Bie, CCO Emirates Biotech; Dorus Everwijn, President GBI; Marc Verbruggen, CEO Emirates Biotech; Tim Schulten, Division President Sulzer Chemtech; Emmanuel Rapendy, Head Polymer and Crystallization, Sulzer Chemtech and Christophe Miegeville, EPC Project Officer Emirates Biotech © Emirates Biotech

Marc Verbruggen, CEO of Emirates Biotech, commented: “Signing this equipment supply contract with Sulzer represents a decisive step forward for Emirates Biotech. With proprietary equipment now secured, we are firmly entering the execution phase. This is a major commitment – not just financially, but strategically – as we lay the foundation for a state-of-the-art PLA facility that will anchor the region’s transition to sustainable materials.”

Samsung E&A will serve as the contractor for the PLA facility, integrating Sulzer’s proprietary equipment within the wider plant infrastructure, including utilities, storage facilities and other site services.

Construction is expected to commence in Q4 2025, with the plant operational by early 2028.  

Source

Sulzer, press release, 2025-05-27.

Supplier

Emirates Biotech
Samsung Corp.
Sulzer Chemtech Ltd.

Share

Renewable Carbon News – Daily Newsletter

Subscribe to our daily email newsletter – the world's leading newsletter on renewable materials and chemicals

Subscribe